

Malaysia Results Review

25 August 2023

Property | Real Estate **Buy** (Maintained)

Sunway (SWB MK)

Completion Of Parc Canberra To Lift 3Q23 Earnings

Target Price (Return): MYR2.65 (+39%)
Price (Market Cap): MYR1.91 (USD2,031m)
ESG score: 3.4 (out of 4)
Avg Daily Turnover (MYR/USD) 8.07m/1.72m

- Maintain BUY and MYR2.65 TP, 39% upside with c.3% FY23F yield. Sunway's 2Q23 results are in line. The company's earnings should strengthen in 3Q23, given the completion of Parc Canberra in Singapore. Meanwhile, 1H23 property sales came up to MYR1.5bn, which is on track to achieve management's MYR2.3bn full-year target. We continue to like Sunway. Given its sizeable landbank exposure to Iskandar Malaysia, the company stands to gain from the favourable impact of the Rapid Transit System link and the Johor-Singapore special economic zone.
- 2Q23 results. Among all the divisions, the property development segment recorded the highest QoQ growth, mainly due to higher sales and billings from new and ongoing projects. The property investment unit, however, recorded weaker earnings due to Ramadan (in April), as well as higher utility charges and manpower costs. On an annual basis, EBIT in 2Q22 was lifted by a MYR26.6m gain on disposal of a start-up investment. The healthcare segment, meanwhile, saw stronger contributions from SMC Sunway City and SMC Velocity, mitigating the share of start-up losses of SMC Penang and Sunway Sanctuary. Note that the share of start-up losses of SMC Penang decreased to MYR1.3m, from MYR2.2m in the previous quarter. Just like 2Q22, a single-tier first interim DPS of 2 sen was declared.
- Singapore project contributed to stronger sales in 2Q23. New property sales came up to MYR1bn (1Q23: MYR505m), bringing the 1H23 total to MYR1.5bn. Despite the recent tightening measures, take-up rates in Terra Hills and The Continuum, launched in February and April, were still rather decent at 36% and 27%. Projects in Singapore contributed MYR763m. For Malaysia, the key contributors were Velocity TWO (MYR161m) and Sunway Flora Residences in Bukit Jalil (MYR151m). Sales for Sunway Flora and Sunway Dora in Bayan Baru launched in 1Q23 were encouraging, with 74% of units taken up (including bookings) for both projects. However, sales for Jernih Residence in Kajang and Sunway Alishan in Cheras were slower (48%- and 35%-sold, vs 39%- and 30%-sold in 1Q23). Launches for the rest of the year (total GDV: MYR320m) will mostly be in Iskandar Malaysia, including semi-detached houses and bungalows at Lenang Heights, and landed linked homes in Sunway Iskandar. As more contractual sales kick in, Sunway should be able to hit its MYR2.3bn sales target by year-end.
- We maintain our earnings forecasts. Parc Canberra and Parc Central are
 expected to be completed in 3Q23 and 1Q24, and the accumulated
 progressive profits from both projects are now worth MYR131m. Sunway's
 unbilled sales and outstanding construction orderbook stood at MYR4.86bn
 and MYR5.8bn, vs MYR4.39bn and MYR6bn in 1Q23.
- ESG. Our SOP valuation includes an 8% ESG premium on its intrinsic value, given our 3.4 ESG score (out of 4) for the company.

Forecasts and Valuation	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
Total turnover (MYRm)	3,714	5,195	5,417	5,831	6,388
Recurring net profit (MYRm)	265	677	721	785	847
Recurring net profit growth (%)	(42.5)	155.1	6.5	8.8	8.0
Recurring EPS (MYR)	0.05	0.12	0.12	0.13	0.14
DPS (MYR)	0.03	0.06	0.05	0.06	0.06
Recurring P/E (x)	42.25	16.56	15.70	14.57	13.63
P/B (x)	0.93	0.89	0.87	0.85	0.83
Dividend Yield (%)	1.5	2.9	2.6	2.9	3.1
Return on average equity (%)	2.7	5.5	5.7	6.0	6.2
Net debt to equity (%)	44.9	52.3	53.0	51.0	49.7

Source: Company data, RHB


Analyst

Loong Kok Wen, CFA +603 9280 8861 loong.kok.wen@rhbgroup.com



Share Performance (%)

	YTD	1m	3m	6m	12m
Absolute	17.9	14.4	23.2	17.2	15.1
Relative	21.3	13.0	20.7	18.0	16.6
52-wk Price low/	high (MYR	2)		1.47	- 1.92



Source: Bloomberg

Overall ESG Score: 3.4 (out of 4)

E: EXCELLENT

Sunway City is a Green Building Index (GBI)-certified township. The company managed to avoid 40,131 tonnes of CO2e emitted over 2015-2019, and 1% of its electricity consumed is from renewable sources (in 2019). Its main townships also have more than 40% open space, with greenscapes and bluescapes incorporated.

S: EXCELLENT

Sunway has given donations to aid the underserved communities in the B40 group, the disabled, youth, women, children and senior citizens. The Good Run in Oct 2019 raised MYR275k to support medical treatment costs for cancer patients in the B40 group.

G: EXCELLENT

56% of Board members are independent directors. Sunway has an in-house investor relations team that is easily accessible and holds investor meetings, embodying good transparency and disclosure practices.



25 August 2023

Financial Exhibits

ASIA
Malaysia
Property
Sunway
SWB MK
Buy

Valuation basis

Our SOP valuation comprises:

- i. 40% discount to its property RNAV;
- ii. 12x FY23F P/E for the trading and building materials division;
- iii. 18.5x EV/EBITDA for the healthcare segment;
- iv. A 10% holding company discount applied.

Key drivers

- i. New property sales;ii. Disposal of investment properties.

Weaker-than-expected market conditions.

Company Profile

Sunway is a well-known developer in the Klang Valley. Its flagship project Bandar Sunway is a well-established integrated township. It has successfully transformed mining land into a matured residential and commercial real estate cluster.

Financial summary (MYR)	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
Recurring EPS	0.05	0.12	0.12	0.13	0.14
EPS	0.05	0.12	0.12	0.13	0.14
DPS	0.03	0.06	0.05	0.06	0.06
BVPS	2.05	2.14	2.19	2.24	2.30
Return on average equity (%)	2.7	5.5	5.7	6.0	6.2
Return on average assets (%)	1.3	2.6	2.7	2.8	3.0

Valuation metrics	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
Recurring P/E (x)	42.25	16.56	15.70	14.57	13.63
P/B (x)	0.9	0.9	0.9	0.9	0.8
Dividend Yield (%)	1.5	2.9	2.6	2.9	3.1
EV/EBITDA (x)	39.75	25.83	27.65	23.34	21.06

Income statement (MYRm)	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
Total turnover	3,714	5,195	5,417	5,831	6,388
Gross profit	798	1,353	1,346	1,495	1,642
EBITDA	458	749	719	860	968
Depreciation and amortisation	(131)	(130)	(124)	(133)	(139)
Operating profit	327	618	595	728	829
Net interest	55	(14)	(32)	(52)	(70)
Pre-tax profit	466	920	1,001	1,090	1,177
Taxation	(116)	(167)	(200)	(218)	(235)
Reported net profit	294	677	721	785	847
Recurring net profit	265	677	721	785	847

Cash flow (MYRm)	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
Change in working capital	(468)	(661)	(73)	(56)	(274)
Cash flow from operations	202	180	688	810	665
Capex	0	(373)	(692)	(430)	(375)
Cash flow from investing activities	(2,891)	(929)	(573)	(232)	(107)
Dividends paid	(163)	(323)	(296)	(329)	(363)
Cash flow from financing activities	3,318	62	(391)	(423)	(456)
Cash at beginning of period	2,269	2,817	1,959	1,785	1,900
Net change in cash	628	(687)	(276)	154	102
Ending balance cash	2,897	2,130	1,683	1,939	2,002

Balance sheet (MYRm)	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
Total cash and equivalents	2,817	1,959	1,785	1,900	1,894
Tangible fixed assets	16,592	17,677	18,244	18,542	18,779
Intangible assets	433	441	441	441	441
Total other assets	60	61	278	461	626
Total assets	25,087	26,058	27,219	28,098	29,073
Short-term debt	4,094	4,919	4,919	4,919	4,919
Total long-term debt	4,622	4,137	4,316	4,426	4,517
Total liabilities	11,963	12,496	13,152	13,489	13,885
Shareholders' equity	12,035	12,529	12,954	13,409	13,894
Minority interests	1,089	1,033	1,113	1,200	1,294
Total equity	13,123	13,562	14,067	14,609	15,188
Total liabilities & equity	25,087	26,058	27,219	28,098	29,073

Key metrics	Dec-21	Dec-22	Dec-23F	Dec-24F	Dec-25F
Revenue growth (%)	(3.1)	39.9	4.3	7.6	9.5
Recurring net profit growth (%)	(42.5)	155.1	6.5	8.8	8.0
Recurrent EPS growth (%)	(49.6)	155.1	5.5	7.8	6.9
Gross margin (%)	21.5	26.0	24.9	25.6	25.7
Recurring net profit margin (%)	7.1	13.0	13.3	13.5	13.3
Dividend payout ratio (%)	55.3	47.7	41.1	42.0	42.8

Source: Company data, RHB



Results At a Glance

Figure 1: Quarterly results

FYE Dec (MYR mil)	2Q22	1Q23	2Q23	QoQ (%)	YoY (%)	1H22	1H23	YoY (%)	Comments
Turnover	1,280.4	1,263.7	1,468.2	16.2	14.7	2,392.8	2,731.9	14.2	
Prop dev	286.4	247.8	362.1	46.1	26.4	444.6	609.9	37.2	Revenue was higher QoQ due to higher sales and progress billings from new and ongoing local projects
Prop invt	149.6	209.9	199.4	(5.0)	33.3	270.7	409.3	51.2	The slower revenue QoQ was due to lower visitorship during the fasting month in April and fewer number of school and public holiday during the quarter.
Construction	316.8	327.9	404.1	23.2	27.5	685.5	732.0	6.8	The higher sequential revenue was mainly due to higher progress billings from local projects.
Trading & Manufacturing	264.8	224.1	227.8	1.7	(14.0)	469.8	451.9	(3.8)	-
Quarry	101.1	78.2	94.5	20.8	(6.5)	177.2	172.7	(2.5)	
Investment holdings	1.8	2.3	1.9	n.m.	n.m.	3.7	4.2	13.5	
Others	159.8	173.5	178.4	2.8	11.6	341.3	351.9	3.1	
EBIT	166.3	113.4	140.0	23.5	(15.8)	238.4	253.4	6.3	2Q22 EBIT was lifted by MYR26.6m gain on disposal of a start-up investment.
EBIT Margin (%)	13.0%	9.0%	9.5%			10.0%	9.3%		
Prop dev	24.7	14.2	44.7	215.0	81.3	29.0	58.9	102.8	
Prop invt	53.9	45.6	28.2	(38.1)	(47.6)	68.7	73.9	7.5	EBIT was weaker as operating costs were higher from higher utility charges and manpower costs given the implementation of minimum wage by the government.
Construction	43.9	43.7	48.8	11.6	11.3	87.4	92.6	5.9	
Trading & Manufacturing	10.8	10.9	12.4	14.0	15.0	21.7	23.3	7.3	
Quarry	2.4	4.4	5.2	16.2	114.6	7.4	9.6	29.5	
Investment holdings	(6.6)	(17.9)	(13.4)	n.m.	102.9	(28.8)	(31.3)	8.5	
Others	37.2	12.3	14.1	14.3	(62.2)	52.9	26.4	(50.1)	
Exceptional items	0.0	0.0	(3.1)	n.m.	n.m.	(7.5)	(3.1)	n.m.	
Finance cost	(28.2)	(4.1)	(14.6)	259.7	(48.2)	(12.4)	(18.6)	50.5	
Asso & jv	76.9	82.7	77.6	(6.2)	8.0	176.1	160.3	(9.0)	
Other Income	0.0	0.0	0.0	n.m.	n.m.	0.0	0.0	0.0	
Pretax profit	215.0	192.0	203.0	5.7	(5.6)	402.1	395.0	(1.8)	
PBT margin (%)	16.8%	15.2%	13.8%			16.8%	14.5%		
Tou	(22.0)	(22.2)	(20.0)	(7.4)	20.4	(E4.7)	(04.4)	22.0	
Tax Tax (%)	(23.8)	(33.3) 17.3%	(30.8)	(7.4)	29.4	(51.7) 12.9%	(64.1) 16.2%	23.9	
PAT	191.2	158.8	172.2	8.5	(9.9)	350.4	331.0	(5.5)	
MI	0.0	(17.1)	(22.3)	-	n.m.	(19.1)	(39.4)	106.6	
Net profit	191.2	141.6	149.9	5.9	(21.6)	331.3	291.6	(12.0)	
Core net profit	191.2	141.6	146.8	3.7	(23.2)	323.8	288.5		Within expectations.
Net margin (%)	14.9	11.2	10.0						
EPS (sen)	2.9	2.0	2.5			5.3	5.3		
NTA (RM)	2.10	2.16	2.15			2.10	2.10		
DPS (sen)	2.0	0.0	2.0			2.0	2.0		
EBIT margin:									
Prop dev	8.6%	5.7%	12.3%			6.5%	6.5%		
Prop invt	36.0%	21.7%	14.2%			25.4%	25.4%		
Construction	13.8%	13.3%	12.1%			12.8%	12.8%		
Trading & Manufacturing	4.1%	4.9%	5.5%			4.6%	4.6%		
Quarry	2.4%	5.7%	5.5%			4.2%	4.2%		
Investment holdings	n.m.	n.m.	n.m.			n.m.	n.m.		
-									

Source: Company data, RHB



Figure 2: RNAV estimate

		Remaining	Remaining		
Developments		Landbank (acre)	GDV (MYR m)	Effective stake	NPV @ 10
Selangor/KL					
Sunway Damansara		13.19	938.30	60%	94.
Sunway South Quay		32.90	2,486.70	100%	347.
Sunway Monterez		4.40	38.00	60%	3.
Sunway Semenyih		523.11	728.59	70%	58.
Sunway Cheras		2.92	4.50	100%	0.
Sunway Duta		3.16	120.00	60%	7.
Sunway Resort City		7.7	660	100%	104.
Sunway Living Space (Sri Hartamas)		5.09	850.00	100%	103.
Sunway Velocity 2		1.01	80.00	60%	3.
Sunway Velocity 3		5.50	1,200.00	60%	65.
New land in Cochrane		5.52	1,150.00	100%	108.
Sunway Tower KL 1		0.92	240.00	100%	21.
Sunway Termuning		31.20	13.59	80%	0.
Mont Putra, Rawang		158.00	156.00	100%	13.
Kelana Jaya		13.96	860.00	100%	67.
Sunway Belfield		1.65		100%	-
Jernih Residence, Kajang		2.44	264.00	60%	14.
USJ 1		14.80	1,400.00	100%	110.
Mutiara Bukit Jalil		8.02	697.00	100%	52.
Kuang land		245.00	2,000.00	100%	122.
Dengkil (Emerald Tycoon)		61.23	813.90	100%	46.
Perak					
Sunway City Ipoh		324.1	3,746.38	96%	492.
Penang					
Sunway Hills		80.70		100%	-
Sunway Wellesley, Bukit Mertajam		50.66	710.47	100%	73.
Paya Terubong		19.79	1,500.00	100%	143.
Sunway Tunas, Balik Pulau		9.37	20.60	100%	2.
Sunway Betong, Balik Pulau		19.87	16.80	100%	1.
S'pore					
Terra Hills Pasir Panjang		4.79	2,873.00	30%	87.
The Continuum Tanjong Katong		6.06	7,480.00	30%	129.
Johor					
Bukit Lenang		30.48	850.00	80%	64.
Medini		530.44	10,505.00	60%	505.
Pendas		1,071.47	18,000.00	100%	1,073.
China					
Γianjin Phase 3		5.87	688.80	60%	33.
Unbilled sales					586.
TOTAL		3,517.97	67,900.09		4,573.3
Investment properties		Est. market value	Book value	Equity	Net surplu
Monash University Campus		(MYR m) 375.0	(MYR m) 375.0	interest 100%	(MYR ı
Monash U Residence		465.0	465.0	100%	
Sunway Geo Tower		168.0	112.0	100%	56
Sunway Hotel Georgetown				100%	22
Sunway Hotel Georgetown Sunway Hotel Phnom Penh		60.0 17.0	37.6 17.0	53%	22
Sunway Hotel Hanoi		1.0	1.0	100%	
•					
Sunway Giza		52.0	52.0	60%	505
Sunway Velocity Mall		1,900.0	908.5	59%	585
Sunway Velocity Hotel		112.0	112.0	39%	
Sunway Citrine Hub		42.0	42.0	60%	(
Sunway Geo Avenue		94.0	47.0	100%	47
Sunway Big Box retail hub		220.0	220.0	100%	(
Sunway Visio Tower		100.0	100.0	100%	(
Sunway V Office		160.0	160.0	100%	(
·					
Subtotal					5,236.7
Sunway V Office Subtotal Shareholders' equity (ex cons. & healthcare)					5,236.7 12,872.5
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal					5,236.7 12,872.5 18,109.2
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal Discount to Property RNAV					5,236.7 12,872.5 18,109.2 40
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal Discount to Property RNAV					5,236.7 12,872.5 18,109.2 40
Subtotal Shareholders' equity (ex cons. & healthcare) Total Discount to Property RNAV Discounted Property RNAV	Market value	160.0	160.0	100% PE target	5,236.7 12,872.5 18,109.2 40 10,865.5
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal Discount to Property RNAV Discounted Property RNAV	(MYR m)	160.0 Book value (MYR m)	160.0	100%	5,236.7 12,872.5 18,109.2 40 10,865.5 Equity value surpl (MYR
Subtotal Shareholders' equity (ex cons. & healthcare) Total Discount to Property RNAV Discounted Property RNAV Other divisions 40.9% Sunway REIT	(MYR m) 2,241.2	Book value (MYR m) 1,479.0	160.0	100% PE target	5,236.7 12,872.5 18,109.2 40 10,865.5 Equity value surpl (MYR) 762.1
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal Discount to Property RNAV Discounted Property RNAV Other divisions 40.9% Sunway REIT 54.6% Sunway Construction	(MYR m)	160.0 Book value (MYR m)	Est. FY24 earnings (MYR m)	PE target (x)	5,236.7 12,872.5 18,109.2 40 10,865.5 Equity value surph (MYR 762.1 624.3
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal Discount to Property RNAV Discounted Property RNAV Other divisions 10.9% Sunway REIT 54.6% Sunway Construction	(MYR m) 2,241.2	Book value (MYR m) 1,479.0	Est. FY24 earnings (MYR m)	PE target (x)	5,236.7 12,872.5 18,109.2 40 10,865.5 Equity value surpl (MYR. 762.1 624.3 840.0
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal Discount to Property RNAV Discounted Property RNAV Other divisions 40.9% Sunway REIT 64.6% Sunway Construction Others	(MYR m) 2,241.2	Book value (MYR m) 1,479.0	Est. FY24 earnings (MYR m)	PE target (x)	5,236.7 12,872.5 18,109.2 40 10,865.5 Equity value surpl (MYR 762.1 624.3
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal Discount to Property RNAV Discounted Property RNAV Other divisions 40.9% Sunway REIT 64.6% Sunway Construction Others	(MYR m) 2,241.2	Book value (MYR m) 1,479.0	Est. FY24 earnings (MYR m) 70 Est. FY24 EBITDA	PE target (x) 12 EV/EBITDA (x)	5,236.7 12,872.5 18,109.2 40 10,865.5 Equity value surpl (MYR 762.1 624.3 840.0
Subtotal Shareholders' equity (ex cons. & healthcare) Total Discount to Property RNAV Discounted Property RNAV Other divisions 40.9% Sunway REIT 54.6% Sunway Construction Others 84% Sunway Healthcare	(MYR m) 2,241.2	Book value (MYR m) 1,479.0	Est. FY24 earnings (MYR m) 70 Est. FY24 EBITDA	PE target (x) 12 EV/EBITDA (x)	5,236.7 12,872.5 18,109.2 4(10,865.5 Equity value surpl (MYR 762.1 624.3 840.0 Equity vall 3,497.8
Subtotal Shareholders' equity (ex cons. & healthcare) Total Discount to Property RNAV Discounted Property RNAV Other divisions 40.9% Sunway REIT 54.6% Sunway Construction Others 34% Sunway Healthcare Total ESOS proceeds	(MYR m) 2,241.2	Book value (MYR m) 1,479.0	Est. FY24 earnings (MYR m) 70 Est. FY24 EBITDA	PE target (x) 12 EV/EBITDA (x)	5,236.7 12,872.5 18,109.2 40 10,865.5 Equity value surpl (MYR 762.1 624.3 840.0 Equity val 3,497.8
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal Discount to Property RNAV Discounted Property RNAV Dther divisions 40.9% Sunway REIT 54.6% Sunway Construction Dthers 34% Sunway Healthcare Fotal ESOS proceeds Warrants conversion @ MYR1.56	(MYR m) 2,241.2	Book value (MYR m) 1,479.0	Est. FY24 earnings (MYR m) 70 Est. FY24 EBITDA	PE target (x) 12 EV/EBITDA (x)	5,236.7 12,872.5 18,109.2 40 10,865.5 Equity value surpl (MYR 762.1 624.3 840.0 Equity val 3,497.8
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal Discount to Property RNAV Discounted Property RNAV Dther divisions 40.9% Sunway REIT 54.6% Sunway Construction Dthers B4% Sunway Healthcare Fotal ESOS proceeds Warrants conversion @ MYR1.56 Fotal RNAV	(MYR m) 2,241.2	Book value (MYR m) 1,479.0	Est. FY24 earnings (MYR m) 70 Est. FY24 EBITDA	PE target (x) 12 EV/EBITDA (x)	5,236.7 12,872.5 18,109.2 40 10,865.5 Equity value surpl (MYR 762.1 840.0 Equity val 3,497.8 16,589.9 151.2 1,044.4 17,785.6
Subtotal Shareholders' equity (ex cons. & healthcare) Total Discount to Property RNAV Discounted Property RNAV Dither divisions 40.9% Sunway REIT 54.6% Sunway Construction Dithers 84% Sunway Healthcare Fotal ESOS proceeds Warrants conversion @ MYR1.56 Total RNAV Holding company discount	(MYR m) 2,241.2	Book value (MYR m) 1,479.0	Est. FY24 earnings (MYR m) 70 Est. FY24 EBITDA	PE target (x) 12 EV/EBITDA (x)	5,236.7 12,872.5 18,109.2 4(10,865.5 Equity value surpl (MYR 762.1 624.3 840.0 Equity val 3,497.8 16,589.9 151.2 1,044.4 17,785.6
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal Discount to Property RNAV Discounted Property RNAV Dither divisions 40.9% Sunway REIT 54.6% Sunway Construction Dithers 34% Sunway Healthcare Fotal ESOS proceeds Warrants conversion @ MYR1.56 Fotal RNAV Holding company discount Discounted RNAV	(MYR m) 2,241.2	Book value (MYR m) 1,479.0	Est. FY24 earnings (MYR m) 70 Est. FY24 EBITDA	PE target (x) 12 EV/EBITDA (x)	5,236.7 12,872.5 18,109.2 4(10,865.5 Equity value surpl (MYR 762.1 624.3 840.0 Equity val 3,497.8 16,589.9 151.2 1,044.4 17,785.6 16,007.0
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal Discount to Property RNAV Discounted Property RNAV Discounted Property RNAV Discounted Property RNAV Discounted Property RNAV Discounted RNAV Healthcare Fotal SSOS proceeds Warrants conversion @ MYR1.56 Fotal RNAV Holding company discount Discounted RNAV Share base (mil) incl. warrants & ICPS	(MYR m) 2,241.2	Book value (MYR m) 1,479.0	Est. FY24 earnings (MYR m) 70 Est. FY24 EBITDA	PE target (x) 12 EV/EBITDA (x)	5,236.7 12,872.5 18,109.2 40 10,865.5 Equity value surpl (MYR 762.1 840.0 Equity val 3,497.8 16,589.9 151.2 1,044.4 17,785.6 16,007.0 6,525.8
Subtotal Shareholders' equity (ex cons. & healthcare) Fotal Discount to Property RNAV Discounted Property RNAV Dither divisions 40.9% Sunway REIT 54.6% Sunway Construction Dithers 34% Sunway Healthcare Fotal ESOS proceeds Warrants conversion @ MYR1.56 Fotal RNAV Holding company discount Discounted RNAV	(MYR m) 2,241.2	Book value (MYR m) 1,479.0	Est. FY24 earnings (MYR m) 70 Est. FY24 EBITDA	PE target (x) 12 EV/EBITDA (x)	5,236.7 12,872.5 18,109.2 40 10,865.5 Equity value surpl (MYR 762.1 624.3 840.0 Equity val 3,497.8 16,589.9 151.2 1,044.4 17,785.6 10

Source: RHB

Recommendation Chart




Source: RHB, Bloomberg

Date	Recommendation	Target Price	Price
2023-08-17	Buy	2.65	1.92
2023-01-12	Buy	2.06	1.61
2022-11-28	Buy	2.06	1.58
2022-08-24	Buy	2.06	1.66
2022-05-26	Buy	2.06	1.74
2021-11-25	Buy	2.06	1.68
2021-08-25	Buy	2.00	1.77
2021-07-13	Buy	2.02	1.71
2021-06-24	Buy	2.09	1.73
2021-05-26	Buy	1.92	1.66
2021-04-19	Buy	1.95	1.64
2021-04-01	Buy	1.94	1.69
2021-03-16	Buy	1.88	1.64
2020-03-23	Buy	1.86	1.41
2020-02-26	Buy	2.00	1.79

Source: RHB, Bloomberg

ESG Rating History



Source: RHB

RHB Guide to Investment Ratings

Share price may exceed 10% over the next 12 months

Trading Buy: Share price may exceed 15% over the next 3 months, however longer-

term outlook remains uncertain
Share price may fall within the range of +/- 10% over the next Neutral:

12 months

Take Profit: Target price has been attained. Look to accumulate at lower levels Share price may fall by more than 10% over the next 12 months Sell:

Stock is not within regular research coverage Not Rated:

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

RESTRICTIONS ON DISTRIBUTION

This report is issued and distributed in Malaysia by RHB Investment Bank Berhad ("RHBIB"). The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHBIB has no obligation to update its opinion or the information in this report.

Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a



member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

This report is issued and distributed in Singapore by RHB Bank Berhad (through its Singapore branch) which is an exempt capital markets services entity and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad (through its Singapore branch) may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore branch) in respect of any matter arising from or in connection with the report.

United States

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

DISCLOSURE OF CONFLICTS OF INTEREST

RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and associated companies, ("RHBIB Group") form a diversified financial group, undertaking various investment banking activities which include, amongst others, underwriting, securities trading, market making and corporate finance advisory.

As a result of the same, in the ordinary course of its business, any member of the RHBIB Group, may, from time to time, have business relationships with, hold any positions in the securities and/or capital market products (including but not limited to shares, warrants, and/or derivatives), trade or otherwise effect transactions for its own account or the account of its customers or perform and/or solicit investment, advisory or other services from any of the subject company(ies) covered in this research report.

While the RHBIB Group will ensure that there are sufficient information barriers and internal controls in place where necessary, to prevent/manage any conflicts of interest to ensure the independence of this report, investors should also be aware that such conflict of interest may exist in view of the investment banking activities undertaken by the RHBIB Group as mentioned above and should exercise their own judgement before making any investment decisions.

In Singapore, investment research activities are conducted under RHB Bank Berhad (through its Singapore branch), and the disclaimers above similarly apply.

Save as disclosed in the following link RHB Research Conflict Disclosures - Aug 2023 and to the best of our knowledge, RHBIB hereby declares that:

- RHBIB does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
- RHBIB is not a market maker in the securities or capital market products of the subject company(jes) covered in this report.
- None of RHBIB's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report *For the avoidance of doubt, the confirmation is only limited to the staff of research department
- RHBIB did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHBIB did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Save as disclosed in the following link RHB Research Conflict Disclosures - Aug 2023

- RHB Securities (Thailand) PCL does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
 RHB Securities (Thailand) PCL is not a market maker in the securities or capital
- market products of the subject company(ies) covered in this report.
- None of RHB Securities (Thailand) PCL's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
- *For the avoidance of doubt, the confirmation is only limited to the staff of research department
- RHB Securities (Thailand) PCL did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHB Securities (Thailand) PCL did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Indonesia

Save as disclosed in the following link RHB Research Conflict Disclosures - Aug 2023 and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:

- PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest in the securities of the subject company(ies) covered in this report. For the avoidance of doubt, interest in securities include the following:
 - Holding directly or indirectly, individually or jointly own/hold securities or entitled for dividends, interest or proceeds from the sale or exercise of the
 - subject company's securities covered in this report*; Being bound by an agreement to purchase securities or has the right to Being bound or required to buy the remaining securities that are not
 - subscribed/placed out pursuant to an Initial Public Offering*.
 - Managing or jointly with other parties managing such parties as referred to in (a), (b) or (c) above.
- PT RHB Sekuritas Indonesia is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.

 None of PT RHB Sekuritas Indonesia's staff** or associated person serve as a
- director or board member* of the subject company(ies) covered in this report. PT RHB Sekuritas Indonesia did not receive compensation for investment banking
- or corporate finance services from the subject company in the past 12 months. PT RHB Sekuritas Indonesia** did not receive compensation or benefit (including
- gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report:

Notes:

*The overall disclosure is limited to information pertaining to PT RHB Sekuritas Indonesia only.

*The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.

Save as disclosed in the following link RHB Research Conflict Disclosures - Aug 2023 and to the best of our knowledge, the Singapore Research department of RHB Bank Berhad (through its Singapore branch) hereby declares that:

- RHB Bank Berhad, its subsidiaries and/or associated companies do not make a market in any issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies and its analysts do not have a financial interest (including a shareholding of 1% or more) in the issuer covered by the Singapore research analysts in this report.
- 3. RHB Bank Berhad's Singapore research staff or connected persons do not serve on the board or trustee positions of the issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies do not have and have not within the last 12 months had any corporate finance advisory relationship with the issuer covered by the Singapore research analysts in this report or any other relationship that may create a potential conflict of interest.
- 5. RHB Bank Berhad's Singapore research analysts, or person associated or connected to it do not have any interest in the acquisition or disposal of, the securities, specified securities based derivatives contracts or units in a collective investment scheme covered by the Singapore research analysts in this report.

 RHB Bank Berhad's Singapore research analysts do not receive any
- compensation or benefit in connection with the production of this research report or recommendation on the issuer covered by the Singapore research analysts.

Analyst Certification

The analyst(s) who prepared this report, and their associates hereby, certify that:



(1) they do not have any financial interest in the securities or other capital market products of the subject companies mentioned in this report, except for:

Analyst	Company
-	-

(2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.



KUALA LUMPUR

RHB Investment Bank Bhd

Level 3A, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur 50400 Malaysia

Tel: +603 9280 8888 Fax: +603 9200 2216

BANGKOK

RHB Securities (Thailand) PCL

10th Floor, Sathorn Square Office Tower 98, North Sathorn Road, Silom Bangrak, Bangkok 10500 Thailand

Tel: +66 2088 9999 Fax:+66 2088 9799

JAKARTA

PT RHB Sekuritas Indonesia

Revenue Tower, 11th Floor, District 8 - SCBD Jl. Jendral Sudirman Kav 52-53 Jakarta 12190 Indonesia

Tel: +6221 509 39 888 Fax: +6221 509 39 777

SINGAPORE

RHB Bank Berhad (Singapore branch)

90 Cecil Street #04-00 RHB Bank Building Singapore 069531 Fax: +65 6509 0470